Regev, Arie

Treatment with LY 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 172

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report

Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology

Drug-Induced Hepatotoxicity and ProtectionLiver Diseases and Immunity

Cited by 166

Hepatic Events Associated with Atomoxetine Treatment for??Attention-Deficit??Hyperactivity Disorder

Bangs, M. E., Jin, L., Zhang, S., Desaiah, D., Allen, A. J., Read, H. A., Regev, A., & Wernicke, J. F. (2008) · Drug Safety

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 68

Answers to the Most Common Questions About the Hepatic Safety Profile of Duloxetine

Wohlreich, M. M., Acharya, N., Strombom, I., Kuritzky, L., Robinson, M., Heinloth, A. N., Regev, A., & Wernicke, J. F. (2008) · Postgraduate Medicine

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 12